🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Liberia gives experimental Ebola drug to three African doctors

Published 16/08/2014, 23:45
Liberia gives experimental Ebola drug to three African doctors

By Clair MacDougall

MONROVIA (Reuters) - Health care workers in Liberia have administered three doses of the rare, experimental drug ZMapp to three doctors suffering from Ebola, two medical workers in Monrovia told Reuters.

Liberia, the West African country with the highest death toll from the tropical virus at 413, received three doses of the rare serum in a special consignment this week.

Doctors Zukunis Ireland and Abraham Borbor from Liberia and Dr. Aroh Cosmos Izchukwu from Nigeria are the first Africans to receive the treatment. The drug has already been administered to two American healthcare workers and a Spanish priest, all previously working in Liberian hospitals.

The U.S. healthcare workers' health has since improved but the Spanish priest died.

"Three doctors are currently being administered treatment with the experimental Ebola drug ZMapp. Treatment began on Thursday evening," said Dr. Billy Johnson, chief medical officer of John F. Kennedy Medical Centre in Monrovia where two of the doctors served before contracting the deadly virus.

A second healthcare worker at the Elwa centre which is housing the sick doctors confirmed that they were on their third day of a six-day ZMapp treatment.

Details of their condition are not known.

The U.N. health agency said only around 10 to 12 doses of the drug have been made and this raises difficult ethical questions about who should get priority access.

The apparent improvement in the two U.S. healthcare workers' condition has stoked popular pressure to make the drug available to Africans - a cause advocated by the Twitter hashtag group #giveustheserum.

There is currently no vaccine against the highly-contagious disease and other forms of treatment are only designed to relieve symptoms such as fever, vomiting and haemorrhaging.

Up to 90 percent of victims die - a fatality rate so high that the U.S. Centers for Disease Control and Prevention (CDC) classifies the illness as a category A "bioterrorism agent" - although the current outbreak fatality rate is near 60 percent.

Liberia's President Ellen Johnson-Sirleaf has declared a state of emergency due to the outbreak, widely seen as the country's biggest challenge since the 1989-2003 civil war.

Health care workers fighting to stop the disease's spread in often overcrowded and ill-equipped clinics often succumb to Ebola themselves. The World Health Organization says that more than 170 healthcare workers have been infected and at least 81 have died.

U.S. President Barack Obama called Johnson-Sirleaf earlier this week to offer condolences for the country's losses and discussed control measures, Liberia said in a statement.

(Writing by Emma Farge in Dakar; Editing by Marguerita Choy)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.